🔥🐔 BizChicken 🐔🔥

Companies Similar to SCYNEXIS, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Biogen Inc.

Biogen Inc. logo
Market Cap: Highest
Employees: Highest

TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, FAMPYRA, SPINRAZA, FUMADERM, BENEPALI, ADUHELM, IMRALDI, FLIXABI, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS

Biogen Inc. focuses on discovering, developing, manufacturing, and delivering therapies for neurological and neurodegenerative diseases, including multiple sclerosis, spinal muscular atrophy, plaque psoriasis, Alzheimer's disease, and various cancers and autoimmune conditions.

Tags: biotechnology, multiple sclerosis, neurodegenerative diseases, neurological diseases, pharmaceuticals

Symbol: BIIB

Recent Price: $150.19

Industry: Drug Manufacturers - General

CEO: Mr. Christopher A. Viehbacher

Sector: Healthcare

Employees: 7570

Address: 225 Binney Street, Cambridge, MA 02142

Phone: 617 679 2000

Leadership

  • Christopher A. Viehbacher, President and Chief Executive Officer
  • Susan H. Alexander, Chief Legal Officer
  • Ginger Gregory, Ph.D., Chief Human Resources Officer
  • Jane Grogan, Ph.D., Head of Research
  • Rachid Izzar, Head of Global Product Strategy & Commercialization
  • Adam Keeney, Head of Corporate Development
  • Michael McDonnell, Chief Financial Officer
  • Nicole Murphy, Head of Pharmaceutical Operations and Technology
  • Priya Singhal, M.D., M.P.H., Head of Development and Interim Chief Medical Officer
  • Alisha Alaimo, President, Head of North America
  • Stephen Amato, Head of Investor Relations
  • Natacha Gassenbach, Head of Corporate Affairs, Chief Communications Officer
  • Fraser Hall, President, Head of Intercontinental Region
  • Wolfram Schmidt, President, Head of Europe
  • Kendra Thomas, Head of Global Workforce Diversity, Equity & Inclusion (DE&I)
  • Caroline Dorsa, Chair of the Board
  • Maria C. Freire, Ph.D., Director
  • William A. Hawkins, Director
  • Susan Langer, Director
  • Jesus B. Mantas, Director
  • Lloyd B. Minor, M.D., Director
  • Monish Patolawala, Director
  • Eric K. Rowinsky, M.D., Director
  • Stephen A. Sherwin, M.D., Director

Last updated: 2024-12-31

Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc. logo
Market Cap: Low
Employees: Low

Therapeutic Candidates (INBRX-109, INBRX-106)

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops biologic therapeutics for life-threatening conditions, with therapeutic candidates in phase 2 clinical trials targeting various cancers.

Tags: biologic therapeutics, biopharmaceutical, cancer treatment, clinical-stage

Symbol: INBX

Recent Price: $15.14

Industry: Biotechnology

CEO: Mr. Mark Paul Lappe

Sector: Healthcare

Employees: 166

Address: 11025 North Torrey Pines Road, La Jolla, CA 92037

Phone: 858-795-4220

Last updated: 2024-12-31

Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc. logo
Market Cap: High
Employees: Low

SNDX-5613, SNDX-6352 (axatilimab), Entinostat

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer treatment, including innovative candidates like SNDX-5613 and SNDX-6352. It collaborates with notable institutions like the National Cancer Institute and has a license agreement with Kyowa Hakko Kirin Co., Ltd.

Tags: Collaborations, Entinostat, Monoclonal Antibody, SNDX-5613, SNDX-6352, biopharmaceutical, cancer therapy, clinical-stage

Symbol: SNDX

Recent Price: $12.52

Industry: Biotechnology

CEO: Mr. Michael A. Metzger M.B.A.

Sector: Healthcare

Employees: 184

Address: 35 Gatehouse Drive, Waltham, MA 02451

Phone: 781 419 1400

Last updated: 2024-12-31

Spero Therapeutics, Inc.

Spero Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Tebipenem pivoxil hydrobromide (HBr), SPR206, SPR720

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for multi-drug resistant bacterial infections and rare diseases in the United States.

Tags: MDR infections, antibiotics, biopharmaceutical, clinical-stage, healthcare, rare diseases

Symbol: SPRO

Recent Price: $1.02

Industry: Biotechnology

CEO: Mr. Satyavrat Shukla C.F.A.

Sector: Healthcare

Employees: 46

Address: 675 Massachusetts Avenue, Cambridge, MA 02139

Phone: 857 242 1600

Leadership

  • Sath Shukla, President and Chief Executive Officer
  • Esther Rajavelu, Chief Financial Officer and Chief Business Officer
  • Timothy Keutzer, Chief Operating Officer
  • James P. Brady, Chief Human Resource Officer
  • Ankit Mahadevia, MD, Chairperson
  • Cynthia Smith, Compensation Committee Chair
  • Frank E. Thomas, Audit Committee Chair
  • Patrick Vink, MD, Nominating and Corporate Governance Chair
  • Milind Deshpande, PhD, Nominating and Corporate Governance Committee Member, Audit Committee Member, and Development Committee Member
  • Scott Jackson, Nominating and Corporate Governance Member and Audit Committee Member
  • John C. Pottage, Jr., M.D., Development Committee Chair
  • Kathleen Tregoning, Compensation Committee Member

Last updated: 2024-12-31

Vaccinex, Inc.

Vaccinex, Inc. logo
Market Cap: Lowest
Employees: Lowest

pepinemab

Vaccinex, Inc., a clinical-stage biotechnology company, focuses on developing targeted biotherapeutics for cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate, pepinemab, is in clinical trials for multiple serious conditions.

Tags: autoimmune disorders, biotechnology, biotherapeutics, cancer, clinical trials, neurodegenerative diseases

Symbol: VCNX

Recent Price: $1.11

Industry: Biotechnology

CEO: Dr. Maurice Zauderer Ph.D.

Sector: Healthcare

Employees: 37

Address: 1895 Mount Hope Avenue, Rochester, NY 14620

Phone: 585 271 2700

Last updated: 2024-12-31

Abivax SA American Depositary Shares

Abivax SA American Depositary Shares logo
Market Cap: Medium
Employees: Lowest

obefazimod

ABIVAX Société Anonyme is a clinical-stage biotechnology company developing therapeutics to modulate the immune response for chronic inflammatory diseases. Their lead drug candidate, obefazimod, is in Phase 3 clinical trials for ulcerative colitis.

Tags: biotechnology, chronic inflammatory diseases, clinical trials, immune response, ulcerative colitis

Symbol: ABVX

Recent Price: $7.05

Industry: Biotechnology

CEO: Mr. Marc M. P. de Garidel M.B.A.

Sector: Healthcare

Employees: 62

Address: 7-11 boulevard Haussmann, Paris, null 75009

Phone: 33 1 53 83 09 63

Leadership

  • Marc de Garidel, MBA, Chief Executive Officer
  • Didier Blondel, EVP, Chief Financial Officer & Board Secretary
  • Fabio Cataldi, MD, Chief Medical Officer
  • Ida Hatoum, Chief People Officer, Chief Compliance Officer
  • David Zhang, PhD, Chief Strategy Officer
  • Pierre Courteille, Pharmacist, MBA, Chief Business Officer
  • Didier Scherrer, PhD, Chief Scientific Officer
  • Jérôme Denis, PhD, EVP, Process Development & Manufacturing
  • Nadège Briancon-Eris, PhD, Senior Vice President, Global Head of Program Management
  • Sylvie Grégoire, PharmD, Chair of the Board
  • Corinna zur Bonsen-Thomas, Co-founder and CEO of RetInSight; Former General Counsel at Baxter/Baxalta International
  • Philippe Pouletty, MD, Founder of Abivax; Managing Partner of Truffle Capital
  • June Lee, MD FACCP, Venture Partner at 5AM Ventures
  • Kinam Hong, MD, MBA, CFA, Partner at the Crossover Fund Sofinnova
  • Troy Ignelzi, CFO of Rapport Therapeutics
  • Camilla Soenderby, Board Member of BB Biotech, F2G, and Affibody; Member of Novo Holdings Advisory Group; Industrial Advisor for EQT
  • Mary Mantock, Senior Vice President, Global Head of Regulatory Affairs
  • Hema Keshava, Senior Vice President, Finance
  • Cristina Damatarca, MD, PgD, Senior Vice President, Global Head of Drug Safety and Pharmacovigilance
  • Patrick Malloy, Senior Vice President, Investor Relations
  • Douglas Jacobstein, MD, Senior Vice President, Global Head of Clinical Development
  • Jennifer Fine, ScD, Senior Vice President, Global Head of HEOR and RWE
  • Kevin Shan, PhD, Vice President, Global Head of Biometrics
  • Chris Rabbat, PhD, Vice President, Global Head of Medical Affairs
  • Ana Sharma, MPH, Vice President, Global Head of Quality
  • Sophie LaCourrege, Vice President, HR Business Partner, Engagement and Culture

Last updated: 2024-12-31

Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. logo
Market Cap: High
Employees: Medium

AXS-05, AXS-07, AXS-12, AXS-14

Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapies for central nervous system disorders such as major depressive disorder, migraine, narcolepsy, and fibromyalgia.

Tags: CNS disorders, biopharmaceutical, clinical trials, depression, fibromyalgia, migraine, narcolepsy

Symbol: AXSM

Recent Price: $84.78

Industry: Biotechnology

CEO: Dr. Herriot Tabuteau M.D.

Sector: Healthcare

Employees: 589

Address: 22 Cortlandt Street, New York, NY 10007

Phone: 212 332 3241

Leadership

  • Herriot Tabuteau, MD, CHIEF EXECUTIVE OFFICER
  • Nick Pizzie, CPA, MBA, CHIEF FINANCIAL OFFICER
  • Mark Jacobson, MA, CHIEF OPERATING OFFICER
  • Hunter Murdock, Esq., GENERAL COUNSEL
  • ari Maizel, Executive Vice President, Head of Commercial
  • Mark Coleman, MD, DIRECTOR
  • Roger Jeffs, PhD, DIRECTOR
  • Susan Mahony, PhD, MBA, DIRECTOR
  • Mark Saad, DIRECTOR

Last updated: 2024-12-31

Biomea Fusion, Inc.

Biomea Fusion, Inc. logo
Market Cap: Medium
Employees: Low

BMF-219

Biomea Fusion, Inc. is a biopharmaceutical company specializing in the discovery and development of covalent small molecule drugs for patients with genetically defined cancers and metabolic diseases. Their lead product candidate, BMF-219, targets multiple cancers.

Tags: BMF-219, biopharmaceutical, cancer, covalent drugs, metabolic diseases

Symbol: BMEA

Recent Price: $3.88

Industry: Biotechnology

CEO: Mr. Thomas Andrew Butler

Sector: Healthcare

Employees: 107

Address: 900 Middlefield Road, Redwood City, CA 94063

Phone: 650 980 9099

Last updated: 2024-12-31

Femasys Inc.

Femasys Inc. logo
Market Cap: Lowest
Employees: Lowest

Fem Bloc, Fem Chec, Fema Seed, Fem Cerv, Fem EMB, Fem Vue

Femasys Inc. is a biomedical company focused on providing innovative healthcare products for women's health, including permanent birth control solutions, artificial insemination products, and biopsy devices. Based in Suwanee, Georgia, the company serves healthcare professionals globally.

Tags: artificial insemination, biomedical, biopsy devices, birth control, global market, women's healthcare

Symbol: FEMY

Recent Price: $1.10

Industry: Medical - Instruments & Supplies

CEO: Ms. Kathy Lee-Sepsick M.B.A.

Sector: Healthcare

Employees: 32

Address: 3950 Johns Creek Court, Suwanee, GA 30024

Phone: 770 500 3910

Last updated: 2024-12-31

Incyte Corporation

Incyte Corporation logo
Market Cap: Highest
Employees: High

JAKAFI, PEMAZYRE, ICLUSIG

Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics, with products like JAKAFI, PEMAZYRE, and ICLUSIG for various cancer treatments.

Tags: ICLUSIG, JAKAFI, PEMAZYRE, biopharmaceutical, cancer treatment, clinical trials, oncology, therapeutics

Symbol: INCY

Recent Price: $68.42

Industry: Biotechnology

CEO: Mr. Herve Hoppenot

Sector: Healthcare

Employees: 2524

Address: 1801 Augustine Cut-Off, Wilmington, DE 19803

Phone: 302 498 6700

Leadership

  • Hervé Hoppenot, Chairman and Chief Executive Officer
  • Paula J. Swain, Executive Vice President, Human Resources
  • Pablo J. Cagnoni, M.D., President, Head of Research and Development
  • Steven H. Stein, M.D., Executive Vice President and Chief Medical Officer
  • Sheila A. Denton, J.D., Executive Vice President and General Counsel
  • Christiana Stamoulis, MBA, Executive Vice President and Chief Financial Officer
  • Barry P. Flannelly, PharmD, MBA, Executive Vice President and General Manager, North America
  • Denise Brashear, Vice President, Head of Global Communications
  • Vijay Iyengar, M.D., Executive Vice President, Global Medical Affairs, Product, and Partnership Strategy (GMAP2S)
  • Lee Heeson, Executive Vice President, Head of Incyte International
  • Michael Morrissey, Executive Vice President and Head of Global Technical Operations
  • Matteo Trotta, MBA, Executive Vice President, General Manager, U.S. Dermatology
  • Xiaozhao Wang, Ph.D., Associate Vice President, Head of Medicinal Chemistry
  • Julian C. Baker, Managing Partner
  • Jean-Jacques Bienaime, Former Chief Executive Officer
  • Otis Brawley, M.D., Bloomberg Distinguished Professor of Oncology and Epidemiology
  • Paul J. Clancy, Former Executive Vice President and Senior Advisor
  • Jacqualyn A. Fouse, Ph.D., Former Chief Executive Officer
  • Edmund P. Harrigan, M.D., Former Senior Vice President of Worldwide Safety and Regulatory
  • Katherine High, M.D., Former President and Head of Research and Development
  • Susanne Schaffert, Ph.D., Former President

Last updated: 2024-12-31

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. logo
Market Cap: High
Employees: Low

NX-2127, NX-5948, NX-1607, NX-0255

Nurix Therapeutics, Inc. is a biopharmaceutical company that focuses on developing small molecule therapies for cancer and immune disorders, with products targeting BTK and CBL-B proteins. The company collaborates with Gilead Sciences and Sanofi.

Tags: BTK degrader, CBL-B inhibitor, biopharmaceutical, cancer, clinical trials, immune disorders

Symbol: NRIX

Recent Price: $18.64

Industry: Biotechnology

CEO: Dr. Arthur T. Sands M.D., Ph.D.

Sector: Healthcare

Employees: 284

Address: 1700 Owens Street, San Francisco, CA 94158

Phone: 415 660 5320

Last updated: 2024-12-31

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. logo
Market Cap: High
Employees: Medium

Crysvita, Mepsevii, Dojolvi, Evkeeza, DTX401, DTX301

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on the development and commercialization of products for rare and ultra-rare genetic diseases worldwide.

Tags: Crysvita, Dojolvi, Evkeeza, Mepsevii, biopharmaceutical, gene therapy, genetic diseases, rare diseases

Symbol: RARE

Recent Price: $42.27

Industry: Biotechnology

CEO: Dr. Emil D. Kakkis M.D., Ph.D.

Sector: Healthcare

Employees: 1276

Address: 60 Leveroni Court, Novato, CA 94949

Phone: 415 483 8800

Last updated: 2024-12-31

scPharmaceuticals Inc.

scPharmaceuticals Inc. logo
Market Cap: Low
Employees: Low

FUROSCIX

sc Pharmaceuticals Inc. is a pharmaceutical company focused on developing and commercializing pharmaceutical products, with a lead product candidate, FUROSCIX, aimed at treating congestion in heart failure patients using an on-body infusor.

Tags: antibiotics, drug development, healthcare, heart failure, pharmaceuticals

Symbol: SCPH

Recent Price: $3.50

Industry: Biotechnology

CEO: Mr. John H. Tucker

Sector: Healthcare

Employees: 135

Address: 2400 District Avenue, Burlington, MA 01803

Phone: 617 517 0730

Leadership

  • John H. Tucker, President and Chief Executive Officer
  • Rachael Nokes, Chief Financial Officer
  • Mike Hassman, Senior Vice President, Technical Operations
  • John Mohr, Pharm.D., FIDP, Senior Vice President, Clinical Development and Medical Affairs
  • William T. Abraham, MD,
  • Mette Kirstine Agger, Co-Founder & CEO, 7TM Pharma A/S
  • Minnie V. Baylor-Henry, President, B-Henry & Associates
  • Sara Bonstein, CFO, Insmed Incorporated
  • Frederick Hudson, Former Partner in Charge of KPMG’s Largest Healthcare Industry Audit Practice Located in the Mid-Atlantic Region
  • Jack A. Khattar, Founder, President & Chief Executive Officer, Supernus Pharmaceuticals
  • Leonard D. Schaeffer, Founding Chairman & CEO, Wellpoint
  • Klaus Veitinger, MD, PhD, Venture Partner, Orbimed
  • Dan Bensimhon, MD, Medical Director Advanced Heart Failure & Mechanical Circulatory Support Program, Cone Health, Greensboro, NC
  • G. Michael Felker, MD, Chief, Heart Failure Service, Division of Cardiology, Duke University School of Medicine
  • Marv Konstam, MD, Professor of Medicine, Tufts University School of Medicine, Chief Physician Executive of the Cardiovascular Center at Tufts Medical Center
  • W. Frank Peacock, MD, FACEP, FACC, FESC, Professor, Vice Chair of Research, Department of Emergency Medicine, Baylor College of Medicine, Ben Taub General Hospital
  • Stuart Russell, MD, Regional Director of Heart Failure Program, Duke University School of Medicine
  • James E. Udelson, MD, Chief, Division of Cardiology, Tufts Medical Center, Professor of Medicine and Radiology Tufts University School of Medicine
  • William Weintraub, MD, Director of Outcomes Research, MedStar Heart and Vascular Institute

Last updated: 2024-12-31

Soligenix, Inc.

Soligenix, Inc. logo
Market Cap: Lowest
Employees: Lowest

SGX301 (Hy Bryte), SGX942, SGX203, SGX302

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases, operating in the Specialized Bio Therapeutics and Public Health Solutions segments.

Tags: Crohn's disease, SGX301, SGX942, biopharmaceutical, oral mucositis, psoriasis, rare diseases

Symbol: SNGX

Recent Price: $2.91

Industry: Biotechnology

CEO: Dr. Christopher J. Schaber Ph.D.

Sector: Healthcare

Employees: 13

Address: 29 Emmons Drive, Princeton, NJ 08540

Phone: 609 538 8200

Leadership

  • Christopher J. Schaber, PhD, Chairman, President and Chief Executive Officer
  • Gregg A. Lapointe, CPA, MBA, Board Director
  • Diane L. Parks, MBA, Board Director
  • Robert J. Rubin, MD, Board Director
  • Jerome Zeldis, MD, PhD, Board Director

Last updated: 2024-12-31

Vincerx Pharma, Inc.

Vincerx Pharma, Inc. logo
Market Cap: Lowest
Employees: Lowest

VIP152

Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company focused on researching and developing therapies to address unmet medical needs for cancer treatment in the United States. Their lead product candidate, VIP152, is a cyclin-dependent kinase-9 inhibitor for advanced cancer.

Tags: biopharmaceutical, cancer treatment, clinical-stage, oncology, therapy development

Symbol: VINC

Recent Price: $0.33

Industry: Biotechnology

CEO: Dr. Ahmed M. Hamdy M.D.

Sector: Healthcare

Employees: 42

Address: 260 Sheridan Avenue, Palo Alto, CA 94306

Phone: 650 800 6676

Last updated: 2024-12-31

VYNE Therapeutics Inc.

VYNE Therapeutics Inc. logo
Market Cap: Lowest
Employees: Lowest

FCD105, FMX114, VYN201, VYN202

VYNE Therapeutics Inc. is a pharmaceutical company specializing in developing therapeutics for immuno-inflammatory conditions. Key products include FCD105 for acne vulgaris, FMX114 for atopic dermatitis, and BET inhibitors VYN201 and VYN202 for skin and other immuno-inflammatory diseases.

Tags: BET inhibitors, acne vulgaris, atopic dermatitis, immuno-inflammatory, pharmaceutical, therapeutics

Symbol: VYNE

Recent Price: $3.19

Industry: Biotechnology

CEO: Mr. David T. Domzalski

Sector: Healthcare

Employees: 10

Address: 520 U.S. Highway 22, Bridgewater, NJ 08807

Phone: 800 775 7936

Last updated: 2024-12-31

AbbVie Inc.

AbbVie Inc. logo
Market Cap: Highest
Employees: Highest

HUMIRA, SKYRIZI, RINVOQ, IMBRUVICA, VENCLEXTA, MAVYRET, CREON, Synthroid, Linzess/Constella, Lupron

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide, offering a range of therapies including HUMIRA for autoimmune diseases and MAVYRET for HCV infection.

Tags: autoimmune diseases, biotechnology, gastroenterology, healthcare, oncology, pharmaceuticals

Symbol: ABBV

Recent Price: $176.20

Industry: Drug Manufacturers - General

CEO: Mr. Robert A. Michael

Sector: Healthcare

Employees: 50000

Address: 1 North Waukegan Road, North Chicago, IL 60064-6400

Phone: 847 932 7900

Last updated: 2024-12-31

Exelixis, Inc.

Exelixis, Inc. logo
Market Cap: Highest
Employees: Medium

CABOMETYX, COMETRIQ, COTELLIC, MINNEBRO

Exelixis, Inc. is an oncology-focused biotechnology company that discovers, develops, and commercializes new medicines to treat cancers, primarily in the United States. Its products include CABOMETYX, COMETRIQ, COTELLIC, and MINNEBRO.

Tags: biotechnology, cancer treatment, oncology, pharmaceuticals

Symbol: EXEL

Recent Price: $33.70

Industry: Biotechnology

CEO: Dr. Michael M. Morrissey Ph.D.

Sector: Healthcare

Employees: 1310

Address: 1851 Harbor Bay Parkway, Alameda, CA 94502

Phone: 650 837 7000

Last updated: 2024-12-31

SCYNEXIS, Inc.

SCYNEXIS, Inc. logo
Market Cap: Lowest
Employees: Lowest

BREXAFEMME (ibrexafungerp tablets)

SCYNEXIS, Inc. is a biotechnology company focused on developing products for the treatment of fungal infections. They offer BREXAFEMME for the treatment of vulvovaginal candidiasis and are developing Ibrexafungerp, an oral and intravenous drug for various fungal infections.

Tags: BREXAFEMME, Biotechnology, Fungal Infections, Ibrexafungerp, Pharmaceuticals

Symbol: SCYX

Recent Price: $1.07

Industry: Drug Manufacturers - Specialty & Generic

CEO: Dr. David Gonzalez Angulo M.D.

Sector: Healthcare

Employees: 29

Address: 1 Evertrust Plaza, Jersey City, NJ 07302-6548

Phone: 201 884 5485

Leadership

  • Armando Anido, Director
  • Steven C. Gilman, Ph.D., Director
  • David Angulo, M.D., President and Chief Executive Officer
  • Scott Sukenick, Chief Legal Officer
  • Ivor Macleod, MBA, CPA, Chief Financial Officer
  • Daniella Gigante, Vice President, Human Resources and Information Technology
  • Rossana Ferrara-Pontoriero, Ph.D., Vice President, Business Development and Alliance Management
  • Guy Macdonald, Chairman of the Board
  • Ann F. Hanham, Ph.D., Director
  • David Hastings, Director
  • Philippe Tinmouth, Director

Last updated: 2024-12-31

Ventyx Biosciences, Inc.

Ventyx Biosciences, Inc. logo
Market Cap: Low
Employees: Low

VTX958

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule product candidates for the treatment of inflammatory diseases and autoimmune disorders. Key products include VTX958 for immune-mediated diseases, VTX002 for ulcerative colitis, and VTX2735 for systemic inflammatory diseases.

Tags: VTX002, VTX2735, VTX958, autoimmune disorders, biopharmaceutical, clinical trials, inflammatory diseases, small molecule

Symbol: VTYX

Recent Price: $2.23

Industry: Biotechnology

CEO: Dr. Raju S. Mohan Ph.D.

Sector: Healthcare

Employees: 73

Address: 662 Encinitas Boulevard, Encinitas, CA 92024

Phone: 760 593 4832

Last updated: 2024-12-31